Trial site
Medipol University Hospital
Istanbul, 34214, TürkiyeNot linked to an institution yet
- 5running trials
- 1closed trial
The trials here
What the 6 trials at this site are about, from their registry records.
- Phase
- Phase 22 trials
- Phase 32 trials
- Phase 2/31 trial
- Status
- Active, not recruiting4 trials
- Completed1 trial
- Recruiting1 trial
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- Regeneron Pharmaceuticals2 trials
- Istanbul Medipol University Hospital1 trial
Running trials
Active, not recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
NCT06787612· Phase 2· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767· Phase 2/3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error